The Present and Future of Biosimilars: Opportunity Abounds

So where are we now with biosimilars? Patent expirations and new bioanalytical advancements over the past couple of years have driven much debate about the development of biosimilars, and the potential threat that these present for current originator products.

Dominique Gouty, Ph.D., of BioAgilytix, offers her expert opinion in this Virtual Podium presentation.

Related Presentations

Western Blot Protocol

Western Blot Protocol

Biomarkers for Lupus Diagnosis and Disease Activity

Biomarkers for Lupus Diagnosis and Disease Activity

Biomarkers and Alzheimer's Disease: Dr. Neil Buckholtz

Biomarkers and Alzheimer's Disease: Dr. Neil Buckholtz